Contact
searchSearch
HMP Global
Login

Genitourinary Cancer Resource Center

Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
Renee Saliby, MD
Videos
Using Intermediate Endpoints to Evaluate the Efficacy of ICIs for Treating Metastatic Renal Cell Carcinoma
03/22/2024

Featuring Renée Saliby, MD

Featuring Renée Saliby, MD
Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.
Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.
Renée Saliby, MD, summarizes her...
03/22/2024
Journal of Clinical Pathways
News
Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of...
03/11/2024
Oncology
From Oncology
Amanda Nizam, MD
Videos
The Potential of Enfortumab Vedotin After Maintenance Avelumab For Treating Patients With Advanced Urothelial Carcinoma: The UNITE Study
03/04/2024

Featuring Amanda Nizam, MD

Featuring Amanda Nizam, MD
Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.
Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.
Amanda Nizam, MD, discusses the...
03/04/2024
Journal of Clinical Pathways
Conference Coverage
Nivolumab Plus Ipilimumab Improved Survival, Response Compared to Sunitinib Among Patients With Advanced Clear Cell Renal Cell Carcinoma
01/31/2024
Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.
Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.
Long-term follow-up data from...
01/31/2024
Oncology
From Oncology
Conference Coverage
Cabozantinib Plus Atezolizumab Significantly Prolonged PFS in Metastatic Castration-Resistant Prostate Cancer
01/25/2024
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3...
01/25/2024
Oncology
From Oncology
News
FDA Approves Belzutifan for Patients With Advanced Renal Cell Carcinoma
01/23/2024
The FDA has granted approval to belzutifan for patients with advanced renal cell carcinoma after they have received a PD-1 or PD-L1 inhibitor and a VEGF-TKI.
The FDA has granted approval to belzutifan for patients with advanced renal cell carcinoma after they have received a PD-1 or PD-L1 inhibitor and a VEGF-TKI.
The FDA has granted approval to...
01/23/2024
Journal of Clinical Pathways
News
FDA Approves Enfortumab Vedotin-Ejfv With Pembrolizumab for Patients With Locally Advanced or Metastatic Urothelial Cancer
01/10/2024
The FDA has granted approval to enfortumab vedotin-ejfv with pembrolizumab for patients with locally advanced or metastatic urothelial cancer.
The FDA has granted approval to enfortumab vedotin-ejfv with pembrolizumab for patients with locally advanced or metastatic urothelial cancer.
The FDA has granted approval to...
01/10/2024
Journal of Clinical Pathways
Dr Rana McKay.
ENGAGING EXPERTS
Antitumor Activity of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
06/19/2023
Dr Rana McKay, a genitourinary medical oncologist at the University of California San Diego, discusses the results of EV-103 cohort K, which assessed the efficacy of enfortumab vedotin monotherapy or in combination with pembrolizumab in...
Dr Rana McKay, a genitourinary medical oncologist at the University of California San Diego, discusses the results of EV-103 cohort K, which assessed the efficacy of enfortumab vedotin monotherapy or in combination with pembrolizumab in...
Dr Rana McKay, a genitourinary...
06/19/2023
Journal of Clinical Pathways
Barragan-Carrillo, MD
Conference Coverage
Impact of Race and Payor Status on Nephrectomy Procedure Type in Patients With Renal Cell Carcinoma
06/08/2023
In an interview with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting, Regina Barragán-Carrillo, MD, discusses her study on the influence of race and payor status on the treatment patterns of partial versus radical nephrectomy...
In an interview with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting, Regina Barragán-Carrillo, MD, discusses her study on the influence of race and payor status on the treatment patterns of partial versus radical nephrectomy...
In an interview with the Journal...
06/08/2023
Journal of Clinical Pathways
Dr Jeff Yorio.
Videos
Costs of Adverse Event Management for Patients with Metastatic Renal Cell Carcinoma Treated With a VEGFR TKI
05/25/2023
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology,...
05/25/2023
Journal of Clinical Pathways

Expert Insights

Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
Renee Saliby, MD
Videos
Using Intermediate Endpoints to Evaluate the Efficacy of ICIs for Treating Metastatic Renal Cell Carcinoma
03/22/2024

Featuring Renée Saliby, MD

Featuring Renée Saliby, MD
Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.
Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.
Renée Saliby, MD, summarizes her...
03/22/2024
Journal of Clinical Pathways
Amanda Nizam, MD
Videos
The Potential of Enfortumab Vedotin After Maintenance Avelumab For Treating Patients With Advanced Urothelial Carcinoma: The UNITE Study
03/04/2024

Featuring Amanda Nizam, MD

Featuring Amanda Nizam, MD
Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.
Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.
Amanda Nizam, MD, discusses the...
03/04/2024
Journal of Clinical Pathways
Dr Rana McKay.
ENGAGING EXPERTS
Antitumor Activity of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
06/19/2023
Dr Rana McKay, a genitourinary medical oncologist at the University of California San Diego, discusses the results of EV-103 cohort K, which assessed the efficacy of enfortumab vedotin monotherapy or in combination with pembrolizumab in...
Dr Rana McKay, a genitourinary medical oncologist at the University of California San Diego, discusses the results of EV-103 cohort K, which assessed the efficacy of enfortumab vedotin monotherapy or in combination with pembrolizumab in...
Dr Rana McKay, a genitourinary...
06/19/2023
Journal of Clinical Pathways
Barragan-Carrillo, MD
Conference Coverage
Impact of Race and Payor Status on Nephrectomy Procedure Type in Patients With Renal Cell Carcinoma
06/08/2023
In an interview with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting, Regina Barragán-Carrillo, MD, discusses her study on the influence of race and payor status on the treatment patterns of partial versus radical nephrectomy...
In an interview with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting, Regina Barragán-Carrillo, MD, discusses her study on the influence of race and payor status on the treatment patterns of partial versus radical nephrectomy...
In an interview with the Journal...
06/08/2023
Journal of Clinical Pathways
Dr Jeff Yorio.
Videos
Costs of Adverse Event Management for Patients with Metastatic Renal Cell Carcinoma Treated With a VEGFR TKI
05/25/2023
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology,...
05/25/2023
Journal of Clinical Pathways
Dr. Tom Hutson, DO, PharmD, Texas A&M College of Medicine
Videos
Efficacy of Nivolumab Plus Cabozantinib vs Sunitinib as Treatment for Renal Cell Carcinoma
04/18/2023
Tom Hutson, DO, PharmD, Texas A&M College of Medicine, discusses his presentation from the 2023 ASCO Genitourinary Symposium, which analyzed the use of nivolumab plus cabozantinib versus sunitinib for treating patients with renal cell...
Tom Hutson, DO, PharmD, Texas A&M College of Medicine, discusses his presentation from the 2023 ASCO Genitourinary Symposium, which analyzed the use of nivolumab plus cabozantinib versus sunitinib for treating patients with renal cell...
Tom Hutson, DO, PharmD, Texas...
04/18/2023
Journal of Clinical Pathways
Dr Rana McKay, medical oncologist at the University of California in San Diego.
Videos
Characterization of FOLH1 Expression in Renal Cell Carcinoma
04/11/2023
Dr Rana McKay, MD, Associate Professor of Medicine at the University of California San Diego, discusses the findings from her study, "Characterization of FOLH1 expression in renal cell carcinoma."
Dr Rana McKay, MD, Associate Professor of Medicine at the University of California San Diego, discusses the findings from her study, "Characterization of FOLH1 expression in renal cell carcinoma."
Dr Rana McKay, MD, Associate...
04/11/2023
Journal of Clinical Pathways
Manish Kohli
Videos
Analyzing the Cost-Effectiveness of Treatment Regimens in Metastatic Hormone-Sensitive Prostate Cancer
03/10/2023
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.
Manish Kohli, MD, compared the...
03/10/2023
Journal of Clinical Pathways
Integrated Clinical and Claims Data Valuable for Clinical Decision Making in Genitourinary Cancer Care
Videos
Integrated Clinical and Claims Data Valuable for Clinical Decision Making in Genitourinary Cancer Care
05/15/2021
Lincy Lal, PhD, discusses the utilization of integrated clinical and claims data to evaluate treatment patterns, resource utilization, and total costs of care during therapy for patients with newly diagnosed genitourinary cancers.
Lincy Lal, PhD, discusses the utilization of integrated clinical and claims data to evaluate treatment patterns, resource utilization, and total costs of care during therapy for patients with newly diagnosed genitourinary cancers.
Lincy Lal, PhD, discusses the...
05/15/2021
Journal of Clinical Pathways
Sawsan Rashdan, MD
Videos
Future Directions in NSCLC Care: Navigating Pathways, Costs, and Cutting-Edge Therapies
11/14/2024
Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.
Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.
Dr. Sawsan Rashdan, an associate...
11/14/2024
Journal of Clinical Pathways
Videos
Evolving Oncology Pathways, CLL Treatment Advances, and the Role of Multidisciplinary Care Teams
11/12/2024
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD,...
11/12/2024
Journal of Clinical Pathways
Kerry Rogers, MD
Videos
Assessing Fixed-Duration Obinutuzumab, Ibrutinib, and Venetoclax in CLL: A 7-Year Follow-Up
11/08/2024
Kerry Rogers, MD, provides a 7-year update on her study that evaluated the progression-free survival and factors associated with undetectable minimal residual disease status after treatment with a fixed-duration combination of obinutuzumab,...
Kerry Rogers, MD, provides a 7-year update on her study that evaluated the progression-free survival and factors associated with undetectable minimal residual disease status after treatment with a fixed-duration combination of obinutuzumab,...
Kerry Rogers, MD, provides a...
11/08/2024
Journal of Clinical Pathways
BDHC Thumbnail
Breaking Down Health Care
Navigating Payer Challenges in Cell and Gene Therapy
11/07/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the challenges and potential solutions for integrating cell and gene therapies—particularly CAR T—into clinical practice and insurance...
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the challenges and potential solutions for integrating cell and gene therapies—particularly CAR T—into clinical practice and insurance...
In this Breaking Down Health...
11/07/2024
Cancer Care Business Exchange
Videos
Navigating Multidisciplinary Care: Insights on Oncology Practice Integration and Pharmaceutical Partnerships
11/04/2024
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at...
11/04/2024
Journal of Clinical Pathways
Videos
Custom Pathways in Oncology: Innovations, Stakeholder Collaboration, and Value-Based Care
11/01/2024
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice...
11/01/2024
Journal of Clinical Pathways
Interview
Treatment Options for NSCLC: A Discussion on Coverage, Clinical Outcomes, and Payer Perspectives
10/30/2024
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research...
10/30/2024
Journal of Clinical Pathways
JB
Interview
The Road Ahead for CLL Research and Treatment: Overcoming Challenges and Embracing Innovations in Patient Care
10/25/2024
Learn about recent advancements in CLL treatment including the potential approval of new combination therapies and the evolving landscape of targeted therapies.
Learn about recent advancements in CLL treatment including the potential approval of new combination therapies and the evolving landscape of targeted therapies.
Learn about recent advancements...
10/25/2024
Journal of Clinical Pathways
Jessica Paulus, ScD
Interview
Insights on Lung Cancer Diagnosis Trends and Screening Challenges in Community Oncology
10/23/2024
In this interview, Jessica Paulus, ScD, senior director of real-world research at Ontada, discusses trends in advanced non–small cell and small cell lung cancer diagnoses, the impact of the COVID-19 pandemic on screening, and the need for...
In this interview, Jessica Paulus, ScD, senior director of real-world research at Ontada, discusses trends in advanced non–small cell and small cell lung cancer diagnoses, the impact of the COVID-19 pandemic on screening, and the need for...
In this interview, Jessica...
10/23/2024
Journal of Clinical Pathways
Federico Cappuzzo, MD, National Cancer Institute Regina Elena
Videos
The Impact of Subcutaneous Formulation of Atezolizumab on Treatment for Patients with Non-Small Cell Lung Cancer
10/17/2024
Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.
Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.
Federico Cappuzzo, MD, discusses...
10/17/2024
Oncology

Newsfeed

Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
Renee Saliby, MD
Videos
Using Intermediate Endpoints to Evaluate the Efficacy of ICIs for Treating Metastatic Renal Cell Carcinoma
03/22/2024

Featuring Renée Saliby, MD

Featuring Renée Saliby, MD
Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.
Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.
Renée Saliby, MD, summarizes her...
03/22/2024
Journal of Clinical Pathways
News
Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of...
03/11/2024
Oncology
Amanda Nizam, MD
Videos
The Potential of Enfortumab Vedotin After Maintenance Avelumab For Treating Patients With Advanced Urothelial Carcinoma: The UNITE Study
03/04/2024

Featuring Amanda Nizam, MD

Featuring Amanda Nizam, MD
Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.
Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.
Amanda Nizam, MD, discusses the...
03/04/2024
Journal of Clinical Pathways
Conference Coverage
Nivolumab Plus Ipilimumab Improved Survival, Response Compared to Sunitinib Among Patients With Advanced Clear Cell Renal Cell Carcinoma
01/31/2024
Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.
Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.
Long-term follow-up data from...
01/31/2024
Oncology
Conference Coverage
Cabozantinib Plus Atezolizumab Significantly Prolonged PFS in Metastatic Castration-Resistant Prostate Cancer
01/25/2024
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3...
01/25/2024
Oncology
News
FDA Approves Belzutifan for Patients With Advanced Renal Cell Carcinoma
01/23/2024
The FDA has granted approval to belzutifan for patients with advanced renal cell carcinoma after they have received a PD-1 or PD-L1 inhibitor and a VEGF-TKI.
The FDA has granted approval to belzutifan for patients with advanced renal cell carcinoma after they have received a PD-1 or PD-L1 inhibitor and a VEGF-TKI.
The FDA has granted approval to...
01/23/2024
Journal of Clinical Pathways
News
FDA Approves Enfortumab Vedotin-Ejfv With Pembrolizumab for Patients With Locally Advanced or Metastatic Urothelial Cancer
01/10/2024
The FDA has granted approval to enfortumab vedotin-ejfv with pembrolizumab for patients with locally advanced or metastatic urothelial cancer.
The FDA has granted approval to enfortumab vedotin-ejfv with pembrolizumab for patients with locally advanced or metastatic urothelial cancer.
The FDA has granted approval to...
01/10/2024
Journal of Clinical Pathways
Barragan-Carrillo, MD
Conference Coverage
Impact of Race and Payor Status on Nephrectomy Procedure Type in Patients With Renal Cell Carcinoma
06/08/2023
In an interview with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting, Regina Barragán-Carrillo, MD, discusses her study on the influence of race and payor status on the treatment patterns of partial versus radical nephrectomy...
In an interview with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting, Regina Barragán-Carrillo, MD, discusses her study on the influence of race and payor status on the treatment patterns of partial versus radical nephrectomy...
In an interview with the Journal...
06/08/2023
Journal of Clinical Pathways
News
Study Analyzes Cabozantinib Plus Nivolumab and Ipilimumab for Patients With aRCC Who Have IMDC Intermediate or Poor Risk Scores
03/30/2023
At the 2023 ASCO GU Cancers Symposium, Thomas Powles, MD, and colleagues presented an analysis of the phase 3 clinical trial COSMIC-313, which compared the use of cabozantinib (C) plus nivolumab (N) and ipilimumab (I) versus a placebo with N...
At the 2023 ASCO GU Cancers Symposium, Thomas Powles, MD, and colleagues presented an analysis of the phase 3 clinical trial COSMIC-313, which compared the use of cabozantinib (C) plus nivolumab (N) and ipilimumab (I) versus a placebo with N...
At the 2023 ASCO GU Cancers...
03/30/2023
Journal of Clinical Pathways
News
Enhancing Survival in Endometrial Cancer: Impact of Immunotherapy and Chemotherapy Combination Therapy
11/13/2024
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with...
11/13/2024
Journal of Clinical Pathways
News
Under 50% of Oncology Practices Offer Survivorship Clinics
11/12/2024
Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.
Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.
Just 41% of oncology practice...
11/12/2024
Journal of Clinical Pathways
Videos
Evolving Oncology Pathways, CLL Treatment Advances, and the Role of Multidisciplinary Care Teams
11/12/2024
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD,...
11/12/2024
Journal of Clinical Pathways
News
Experts Reach Consensus on Myelofibrosis Management, Offering New Hope for Patients
11/08/2024
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international...
11/08/2024
Journal of Clinical Pathways
Conference Coverage
Oncology Pathways Research: Challenges, Adoption, and Future Trends
11/08/2024
In an exclusive interview with the Journal of Clinical Pathways, Cindy Chen, Head of Research at HMP Market Access Insights, shares insights into the challenges, adoption, and future trends of oncology pathways research. Her discussion draws...
In an exclusive interview with the Journal of Clinical Pathways, Cindy Chen, Head of Research at HMP Market Access Insights, shares insights into the challenges, adoption, and future trends of oncology pathways research. Her discussion draws...
In an exclusive interview with...
11/08/2024
Journal of Clinical Pathways
News
Advancing Personalized Treatment in Endometrial Cancer With the HECTOR Deep Learning Model
11/06/2024
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published...
11/06/2024
Journal of Clinical Pathways
Videos
Navigating Multidisciplinary Care: Insights on Oncology Practice Integration and Pharmaceutical Partnerships
11/04/2024
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at...
11/04/2024
Journal of Clinical Pathways
Videos
Custom Pathways in Oncology: Innovations, Stakeholder Collaboration, and Value-Based Care
11/01/2024
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice...
11/01/2024
Journal of Clinical Pathways
News
Influence of Socioeconomic and Demographic Factors on Myelofibrosis Outcomes
10/30/2024
Addressing socioeconomic disparities may improve survival for patients with myelofibrosis, according to a study published in Annals of Hematology.
Addressing socioeconomic disparities may improve survival for patients with myelofibrosis, according to a study published in Annals of Hematology.
Addressing socioeconomic...
10/30/2024
Journal of Clinical Pathways
News
Hypertension and Endometrial Cancer Risk: A Systematic Review and Meta-Analysis
10/25/2024
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and...
10/25/2024
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Oral Anticancer Agent Use Among Older Patients With mRCC
09/20/2021
True or False: Oral anticancer agent adherence in patients with metastatic renal cell carcinoma is low, especially for those with multiple comorbidities and high frailty.
True or False: Oral anticancer agent adherence in patients with metastatic renal cell carcinoma is low, especially for those with multiple comorbidities and high frailty.
True or False: Oral anticancer...
09/20/2021
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Expansion and Managing Genitourinary Cancers
07/16/2021
True or False: Medicaid expansion is associated with a decreased uninsured rate, an increased proportion of early-stage diagnosis for kidney and prostate cancers, and an increased proportion of patients receiving active surveillance for...
True or False: Medicaid expansion is associated with a decreased uninsured rate, an increased proportion of early-stage diagnosis for kidney and prostate cancers, and an increased proportion of patients receiving active surveillance for...
True or False: Medicaid...
07/16/2021
Journal of Clinical Pathways
Quiz
Quiz: Financial Burden of Contemporary Treatments for Prostate Cancer
02/08/2021
02/08/2021
Journal of Clinical Pathways
Quiz
Quiz: Costs of Darolutamide for Castration-Resistant Prostate Cancer
12/12/2020
12/12/2020
Journal of Clinical Pathways
Quiz
Quiz: Does Adjuvant Radiotherapy Improve EFS in Prostate Cancer?
11/25/2020
11/25/2020
Journal of Clinical Pathways
Quiz
Quiz: Does Cabazitaxel Reduce Quality of Life in Metastatic Prostate Cancer?
10/09/2020
10/09/2020
Journal of Clinical Pathways
Quiz
Quiz: Improving Event-Free Survival in Men With Prostate Cancer With Adjuvant Radiotherapy
10/02/2020
10/02/2020
Journal of Clinical Pathways
Quiz
Quiz: Does ADT Improve Long-Term Outcomes for Favorable Intermediate-Risk Prostate Cancer?
09/28/2020
09/28/2020
Journal of Clinical Pathways
Quiz
Quiz: Reduced Spending With Shorter Radiation Regimens for Breast and Prostate Cancer
09/10/2020
09/10/2020
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways
JCP September/October 2024 Issue

Current Issue

October 2024
Volume 10
Issue 5
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
Renee Saliby, MD
Videos
Using Intermediate Endpoints to Evaluate the Efficacy of ICIs for Treating Metastatic Renal Cell Carcinoma
03/22/2024

Featuring Renée Saliby, MD

Featuring Renée Saliby, MD
Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.
Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.
Renée Saliby, MD, summarizes her...
03/22/2024
Journal of Clinical Pathways
News
Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of...
03/11/2024
Oncology
Amanda Nizam, MD
Videos
The Potential of Enfortumab Vedotin After Maintenance Avelumab For Treating Patients With Advanced Urothelial Carcinoma: The UNITE Study
03/04/2024

Featuring Amanda Nizam, MD

Featuring Amanda Nizam, MD
Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.
Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.
Amanda Nizam, MD, discusses the...
03/04/2024
Journal of Clinical Pathways
Conference Coverage
Nivolumab Plus Ipilimumab Improved Survival, Response Compared to Sunitinib Among Patients With Advanced Clear Cell Renal Cell Carcinoma
01/31/2024
Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.
Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.
Long-term follow-up data from...
01/31/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use